1. China Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Shanghai ZJ Bio-Tech Co. Ltd Class A

Shanghai ZJ Bio-Tech Co. Ltd Class A

SSSE:688317
16.82
CNY
-0.57
(-3.28%)
-0.22EPS
2.92BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.37
1.65
0.93
1.06
1.31
1.55
1.76
14.05
10.59
12.02
1.42
0.94
0.69
0.65
Basic EPS, GAAP
0.48
0.57
0.24
0.33
0.35
0.43
0.35
6.38
3.98
3.93
-0.71
-0.67
-0.19
-0.22
Free Cash Flow per Basic Share
0.23
0.09
-0.08
0.09
0.13
0.44
0.36
7.31
0.75
2.64
-0.85
0.31
0.36
- -
Dividend per Share
0.02
0.02
0.31
0.3
0.4
- -
0.45
0.45
1.63
1.37
1.2
0.11
0.02
0.03
Book Value per Share
0.81
0.75
2.35
3.31
3.24
3.65
3.92
10.02
19.66
21.57
19.64
18.93
17.43
16.97
Tangible Book Value per Share
0.77
0.71
2.31
3.27
3.2
3.6
3.87
9.95
19.6
21.51
19.59
18.86
17.36
16.8
Basic Weighted Avg Shares
62
61
136
148
147
145
147
146
191
193
193
190
181
178
Sales/Revenue/Turnover
84
101
127
157
193
224
259
2,052
2,019
2,326
274
179
125
115
Operating Margin (%)
41.45
36.73
31.92
32.04
31.2
31.57
23.92
55.85
45.17
34.76
-16.57
-55.46
-76.78
-75.73
Depreciation Expense
7
7
9
14
20
22
23
20
25
60
67
68
66
- -
Net Income, GAAP
30
35
33
49
52
62
52
932
759
760
-137
-127
-34
-39
Effective Tax Rate (%)
14
16.52
18.53
17.91
16.17
14
15.58
15.97
15.38
15.66
- -
- -
- -
- -
Profit Margin (%)
35.09
34.63
25.67
31.11
26.74
27.78
19.9
45.42
37.57
32.68
-49.89
-71.35
-27.48
-34.12
Working Capital
59
36
251
322
309
363
347
1,198
3,144
3,386
2,929
2,790
2,860
2,764
LT Debt
15
9
- -
- -
- -
- -
- -
- -
- -
6
5
3
287
281
Total Equity
118
110
343
484
473
533
572
1,463
3,827
4,200
3,825
3,637
3,349
3,261
Return on Invested Capital (%)
- -
23.18
13.31
10.04
10.89
12.63
9.53
89.3
28.44
19.04
- -
- -
- -
- -
Return on Capital (%)
- -
27.52
13.88
11.73
10.78
11.95
8.97
93.79
28.68
18.93
- -
- -
- -
- -
Return on Common Equity (%)
- -
30.68
14.34
11.79
10.78
12.4
9.33
91.62
28.68
18.94
-3.41
-3.42
-0.98
-1.16

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
12
10
12
LT Borrowings
284
284
279
LT Finance Leases
3
3
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
192
192
192
Market Capitalization
3,876
3,628
2,921

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,986
2,914
2,878
Cash, Cash Equivalents & STI
2,901
2,826
2,794
Accounts Receivable, Net
31
30
32
Inventories
46
49
38
Total Current Liabilities
127
116
113
Payables & Accruals
- -
- -
- -
ST Debt
12
10
12
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
36.41%
29.93%
-7.92%
Free Cash Flow
186.83%
-17.54%
11.63%
Net Income, GAAP
155.18%
-43.27%
-73.09%
Sales/Revenue/Turnover
63.16%
-27.92%
-30.13%
Total Cash Common Dividend
- -
33.95%
-85.48%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
51
43
43
41
179
2025
32
28
- -
34
125
2026
25
28
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.14
- -
-0.21
-0.6
-0.67
2025
-0.08
0.03
- -
-0.03
-0.19
2026
-0.15
-0.09
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.11
2025
- -
- -
- -
0.01
0.02
2026
0.01
0.01
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jun Bin Shao
Full Time Employees
275
Sector
Health technology
Industry
Biotechnology
Address
Pujiang Wisdom Plaza Shanghai SH China 201114
IPO Date
Jan 18, 2021
Website
liferiver.com.cn
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Shanghai ZJ Bio-Tech Co., Ltd. (688317.SS), also known as Liferiver Bio-Tech, engages in the research, development, production, and sales of molecular genetic diagnostic reagents and instruments. The company's core products include nucleic acid detection kits for applications in emergency public health safety, medical clinical diagnosis, entry-exit inspection and quarantine, and food safety; molecular diagnostic instruments such as real-time PCR systems; and over 500 reagent products covering notifiable infectious diseases, with more than 200 rapid gene diagnostic kits registered as Class III medical devices. These offerings serve hospitals, inspection agencies, and research institutions, primarily within the domestic Chinese market, with business extending to over 100 countries and more than 5,000 customers globally. Founded in 2005 and headquartered at Building 9, No. 2168 Chenhang Road, Minhang District, Shanghai, China, the company operates in the healthcare equipment and supplies sector. In recent developments, Shanghai ZJ Bio-Tech announced its third share repurchase program in 2025 via centralized competitive trading, targeting 60-120 million CNY to reduce registered capital, following the completion of an earlier equity buyback in May 2025 involving 5.83 million shares for 110 million CNY; it also pursues the ongoing acquisition of equity in Shanghai ZJ Bio-Medicine Technology Co., Ltd., initiated in 2022. Additionally, the company signed a strategic cooperation agreement with Sanyou Bio to advance automated development of innovative biologics.